Autologous adipose tissue or adipose tissue with additive adipose-derived mesenchymal stem cells (ADSCs) is used in the breast reconstruction of breast cancer patients who undergo mastectomy. ADSCs play an important role in the angiogenesis and adipogenesis, which make it much better than other materials. However, ADSCs may promote residual tumor cells to proliferate or metastasize, and the mechanism is still not fully understood. In this study, we demonstrated that human ADSCs (hADSCs) could facilitate tumor cells growth after co-injection with MCF7 and ZR-75-30 breast cancer cells (BCCs) by promoting angiogenesis, but hADSCs showed limited effect on the growth of MDA-MB-231 BCCs. Intriguingly, compared with ZR-75-30 tumor cells, MCF7 tumor cells were more potentially promoted by hADSCs in the aspects of angiogenesis and proliferation. Consistent with this, cytokine and angiogenesis array analyses showed that after co-injection with hADSCs, the CXCL1 and CXCL8 concentration were significantly increased in MCF7 tumor, but only moderately increased in ZR-75-30 tumor and did not increase in MDA-MB-231 tumor. Furthermore, we found that CXCL1/8 were mainly derived from hADSCs and could increase the migration and tube formation of human umbilical vein endothelial cells (HUVECs) by signaling via their receptors CXCR1 and CXCR2. A CXCR1/2-specific antagonist (SCH527123) attenuated the angiogenesis and tumor growth in vivo. Our findings suggest that CXCL1/8 secreted by hADSCs could promote breast cancer angiogenesis and therefore provide better understanding of safety concerns regarding the clinical application of hADSCs and suggestion in further novel therapeutic options. STEM CELLS 2017;35:2060-2070 
INTRODUCTION
Breast cancer is one the most frequently diagnosed cancers and one of the leading causes of death in women in much of the world. With the overall survival rates increasing, more and more patients select breast reconstruction as a way to reduce the disabling effects of the mutilation [1, 2] . Autologous fat graft has been used as a filler for breast reconstruction in breast cancer patients following conservative surgery [3] [4] [5] [6] . That is partly because the ADSCs in adipose tissues (about 10 5 ADSCs per gram adipose tissue) can secrete numerous cytokines to benefit the proliferation and angiogenesis of the graft which make it a better graft than other materials [7, 8] .
However, adipocyte and ADSCs secretions can also stimulate tumor cell growth [9] [10] [11] [12] . The "tumor-stroma interaction" can potentially a trigger cancer recurrence by activating residual breast cancer cells (BCCs) in tumor bed. The increasing scientific evidence on the role of the stroma on the carcinogenesis of tumors causes the safety concerns that whether the transfer of ADSCs contained within adipose could increase the risk of breast cancer or cancer recurrence [13, 14] .
Indeed, recent studies have shown that ADSCs may play a vital role in cancer progression [15] [16] [17] [18] . Some clinical trials also indicated that ADSCs may provide a suitable microenvironment for BCC growth which increases the risks of recurrence and metastasis [19, 20] . Besides, ADSCs may contribute to the increasing incidence of obesity-associated breast cancer [21, 22] . Hence, it is of utmost importance to investigate the multifaceted effects of hADSCs on breast cancer progression.
Previous studies have focused on the direct effects of ADSCs act on the tumor cells; however, ADSCs secrete numerous proangiogenic cytokines [23] , which indicates these cells might also mediate breast cancer progression by secreting factors that promoting angiogenesis, while the mechanism underlying the proangiogenic effect of ADSCs is still not fully understood.
BCCs can be divided into estrogen receptor-alpha negative (ERa-) cells and estrogen receptor-alpha positive (ERa1) cells according to the ERa status. We selected both ERa1 and ERa-cells to investigate the impact of hADSCs on angiogenesis of breast tumor xenografts. We found that hADSCs-derived CXCL1/8 promote the angiogenesis, further resulted in proliferation of the ERa1 but not ERa-cancer cells, and inhibition of CXCL1/8-CXCR1/2 axis significantly reversed the promotion effect. Altogether, our findings, for the first time, suggest that CXCL1/8 derived from hADSCs may increase the risk of cancer recurrence after autologous fat graft in reconstructive surgery for breast cancer patients.
MATERIALS AND METHODS

Cell Lines and hADSCs Isolation
MCF7, ZR-75-30, and MDA-MB-231 BCCs (ATCC) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; Gibco), 100 lg/ml streptomycin, 100 units/ml penicillin, and 2 lg/ml puromycin in a humidified atmosphere with 5% CO 2 at 378C. For hADSCs isolation, after giving informed consent, adipose tissues were obtained from women (BMI > 30) undergoing liposuction from the subcutaneous abdominal adipose tissue. The adipose tissues were digested for 45 minutes at 378C using 0.1% I collagenase after washed with phosphate-buffered saline (PBS) thoroughly. The mixture was centrifuged for 12 minutes at 1,000g to obtain the pellets. The pellets were then filtered through a 70-lm nylon mesh to remove cellular debris and incubated at 378C and 5% CO 2 overnight in low glucose Dulbecco's modified Eagle's medium (L-DMEM) (10% FBS, 100 U/ml penicillin, and 100 lg/ml streptomycin). Then the plates were washed with PBS to remove residual red blood cells. The medium was changed every 2 days, and the cells were split upon achieving 80% confluence. hADSCs were used between passages 3 and 8 in experiments. HUVECs (ATCC) were cultured in EGM-2 medium (Lonza) in a humidified atmosphere with 5% CO 2 at 378C.
Flow Cytometry
hADSCs were characterized using cell surface markers by fluorescence-activated cell sorting (FACS) analysis. hADSCs (6 3 10 5 in 100 ll PBS) were incubated with specific fluorescently labeled monoclonal antibodies (CD29, CD166, CD73, CD105, CD90, CD11b, CD31, CD34, CD45, HLA-DR, Biolegend) and then incubated in the dark at 48C for 30 minutes. After washing with PBS twice, the pellet was resuspended in 400 ll PBS and analyzed using the Calibur flow cytometer (BD).
Multilineage Differentiation Assays
To assess the in vitro differentiation potential of cells, we conducted differentiation induction experiments. Briefly, cells were seeded in 6-cm tissue culture dishes up to 80% confluence. The adipogenic induction medium, osteogenic induction medium, and chondrogenic induction medium (Lonza) was prepared according to the manufacturer's instructions as well as the induction procedure. For adipogenic differentiation, cells were fixed and stained by 0.5% oil red O in 60% isopropyl alcohol for 20 minutes to detect lipid droplets after induction. For osteogenic differentiation, cells were stained with 2% Alizarin Red S (pH 4.2) for 20 minutes at room temperature after induction. For chondrogenic differentiation, cells were stained with 1% Alcian blue in 3% glacial acetic acid (pH 2.5) for 30 minutes at room temperature after induction.
Animals and Tumor Transplantation
All animal studies were approved by the Ethics Committee of West China Hospital. Four-to six-week-old female nude mice were purchased from HFK Bioscience. For in vivo tumor transplantation experiments, MCF7 (5 3 10 5 cells) were injected subcutaneously alone or mixed with hADSCs at the ratio of 1:1, 1:2, and 1:3. For SCH5271 [23] inhibitory assay, nude mice implanted with MCF7 alone or with hADSCs (1:1) were administrated with SCH527123 at 50 mg/kg/day. ZR-75-30 (5 3 10 
Cytokine and Angiogenesis Array Analyses
The cytokine profiles of protein (200 lg) from tumor tissue lysates of MCF7 group and coinjected group (1:1) were analyzed using Human Angiogenesis Array Kit and Cytokine Array Kit (R&D) according to the manufacturer's instructions. The detected signals were quantified by pixel density analysis.
Gene Silencing
CXCL1-silencing experiments in MCF7 (MCF7-shCXCL1) and hADSCs (hADSCs-shCXCL1) cells were performed with lentiviral pGLV3/H1/green fluorescent protein (GFP) 1 Puro vectors (Genepharma, Shang Hai, China) based on the manufacturer's instructions and vectors with untargeted sequences were used as negative controls short hairpin RNA (shRNA) control (sh-NC). The knockdown efficiencies were quantified by realtime quantified polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA) on cell-conditioned medium. CXCL8-silencing experiments in MCF7 (MCF7-shCXCL8) and hADSCs (hADSCs-shCXCL8) cells were performed with similar method.
Histopathology and Immunohistochemistry
A 5-lm frozen section of breast tumors xenografts were prepared from MCF7 group and co-injected group, respectively, and then stained with H&E. For immunohistochemistry, the sections were permeabilized with 0.1% Triton X-100 for 15 minutes, then blocked for 45 minutes with 5% bovine serum albumin (BSA) at 378C. The primary antibodies (Anti-CD31, BD Pharmingen; Anti-Ki-67, Abcam) were diluted to 1:50 in PBS and then treated sections at 48C overnight. For fluorescent staining, phycoerythrin-conjugated secondary antibody (red color in the staining) was used to detect the CD31 primary antibody, and FITC-conjugated secondary antibody (green color in the staining) was used to detect the Ki-67 primary antibody. Nuclei were counterstained with DAPI (Invitrogen; blue color). Antibody staining was detected using a fluorescent microscope (Olympus).
Preparation of Conditioned Medium
Conditioned medium (CM) was obtained from 2 3 10 6 MCF7 cells, 2 3 10 6 hADSCs or hADSCs cocultured with MCF7 (1:1). Cultures were washed with 10 ml of PBS three times and incubated for 36 hours with 20 ml serum-free L-DMEM at 378C. Control medium was collected in parallel from tissue culture flasks containing only L-DMEM. The medium was harvested, centrifuged at 1,000g for 3 minutes, then passed through a 0.22-lm filter. CM was stored at 2808C.
Enzyme-Linked Immunosorbent Assay
Approximately 3 3 10 5 MCF7 cells, 3 3 10 5 hADSCs, and mixture cells (1:1) were seeded into well in six-well plates in triplicates to adhere. Then the medium was replaced with serumfree mixed medium (RPMI-1640 and L-DMEM, 1:1) and cultured for 24 hours and same method was used for MCF7- 
Cell Counting Kit-8 Assay
The proliferation rate of MCF7 cells was determined with a Cell Counting Kit-8 (CCK8) at 0, 24, 48, and 72 hours by treatment with vehicle, CXCL1 and CXCL8 (10 ng/ml or 100 ng/ml) according to the manufacturer's instructions.
Endothelial Cell Migration and Capillary Tube Formation Assay
For endothelial cell migration assay, transwell chambers with polycarbonate membrane containing 8 lm pores (Corning) were coated with growth factor-reduced Matrigel (BD). Endothelial cells (1 3 10 5 cells) were plated onto transwell chambers with serum free medium (control); MCF7 cell CM and hADSCs cocultured with MCF7 CM in the absence or presence of indicated agents in triplicates and incubated at 378C for 12 hours. Non-migrated cells were scraped from the upper surface of the membrane with a cotton swab, and migrated cells remaining on the bottom surface were counted after staining with crystal violet with an inverted microscope in several random area.
For in vitro capillary tube formation assay, 1 3 10 4 HUVECs were plated on a growth factor-reduced Matrigel (BD)-coated 96-well plate in triplicates with 100 ll with serum free medium (control); MCF7 cell CM and hADSCs cocultured with MCF7 CM in the absence or presence of indicated agents. After 2 hours of incubation, the plate was examined for capillary tube formation with an inverted microscope in several random area. Neutralizing monoclonal CXCL1 and CXCL8 antibodies (R&D Systems) were used at 10 lg/ml and SCH527123 were used at 10 lM.
Real-Time Quantified Polymerase Chain Reaction
Total RNA was extracted with Trizol Kit(Invitrogen). RT-qPCR was performed using SYBR green with a Bio-Rad machine. Expression data were normalized to U6 mRNA expression. The following primer set sequence for CXCL1 (forward 5 0 -CAGGGAATTCACCCCAAGAACA-3 0 , reverse 5 0 -GGATGCAGGATT GAGGCAAGC-3 0 ) and CXCL8 (forward 5 0 -GGTGCAGTTTTGCCA AGGAG-3 0 , reverse 5 0 -TTCCTTGGGGTCCAGACAGA-3 0 ) were used. U6 (forward 5 0 -CAAGGATGACACGCAAAT-3 0 and reverse 3 0 -TGGAACGCTTCACGAAT-5 0 ) was used as an internal reference point. At the completion of the reaction, DDCt was calculated to quantify mRNA expression.
Statistical Analysis
For statistical analysis, mean values with SEM were presented in most graphs that were derived from at least three repeats of biological experiments. Statistical significance was assessed by unpaired two-tailed Student's t test using GraphPad prism6. p .05 was considered significant. 
RESULTS
Isolation and Characterization of hADSCs
High purity of ADSCs (hADSCs) with obviously fibroblastic morphology was isolated from the human subcutaneous adipose tissue. (Supporting Information Fig. S1 ) The specific cell makers were analyzed by flow cytometry, the cells we obtained express CD166, CD73, CD90, CD29, and CD105 (>99%), while lack CD31, CD45, CD34, CD11b, and HLA-DR (<2%), consistent with the characteristic surface makers expressed on mesenchymal stem cells. We identified the multipotency of these cells by adipogenic differentiation, osteogenic differentiation, and chondrogenic differentiation with differentiation medium. Then, oil red O, Alizarin red, and Alcian blue were used to identify the adipogenic, osteogenic, and chondrogenic capability of the cells by staining the neutral lipids, calcium nodule, and cartilage, respectively. Staining results demonstrated adipogenesis, osteogenesis, and chondrogenesis were successfully induced.
hADSCs Enhance the Human MCF7 and ZR-75-30 but not MDA-MB-231 BCCs Growth in Nude Xenograft Model
To investigate in vivo effects of hADSCs on tumor growth, MCF7, an ERa1 cell line, was injected subcutaneously alone or mixed with hADSCs at the ratio of 1:1, 1:2, and 1:3 (tumor cells to hADSCs). All of the mice developed growing tumors at the injection sites, and the mice that had received injection of mixed cells coupled with hADSCs developed much bigger tumors than that were observed in the mice injected solely with MCF7 tumor cells (Fig. 1A-1C) . In an effort to determine the numbers of residual hADSCs in the tumor tissues, hADSCs were transfected by lentivirus particles expressing GFP (hADSCs-GFP). MCF-7 cells mixed with hADSCs-GFP (1:1) were injected subcutaneously and the tumors were removed on 6, 9, 12, 15, and 18 days after injection. Flow cytometric analysis indicated that the proportion of hADSCs-GFP reduced gradually and only 0.87% hADSCs-GFP retained in the tumors on 18 days after injection (Supporting Information Fig. S2 ). These data indicated that the observed tumor growth could not be attributed to the proliferation of hADSCs, in contrast, the increased tumor volume was mainly due to the proliferation of BCCs. hADSCs also favored ZR-75-30 (ERa1) tumor cells growth at a ratio of 1:3 (tumor cells to hADSCs), though not to the same extent as MCF7 cells (Fig. 1D-1F ). Previous studies indicated that mesenchymal stem cells derived from human bone marrow showed limited effect on the growth of ERa-cell line MDA-MB-231 [24, 25] , consistent with these findings, hADSCs also did not promote the growth of MDA-MB-231 cells (Fig. 1G-1I ). The subcutaneous transplantation of hADSCs (1. 
hADSCs Promote Angiogenesis and Proliferation of Tumor Cells In Vivo
To determine the effect of hADSCs on angiogenesis and proliferation of tumor cells in vivo, immunofluorescence was performed to detect CD31 and Ki-67. CD31 immunostaining was conducted to determine whether co-injected hADSCs increased the vascularity of tumors, vessel counting in immunostained tissue sections indicated that the co-injection of tumor cells with hADSCs could enhance the vascular density significantly ( Fig. 2A-2C) . Besides, double fluorescence immunostaining of CD31 and CD105 (a specific marker for hADSCs but not for MCF7 cells) was conducted with MCF7 and MCF7 1 hADSCs tumors. Consistent with above results, new vessels were detected around the hADSCs niche (Supporting Information Fig. S3 ). Ki-67 immunostaining was conducted to determine whether co-injected hADSCs promote the proliferation of tumor cells. The immunofluorescence results showed that there were limited proliferation cells in the MCF7 alone tumors and the number of Ki-67-positive cells were greater in MCF7 1 hADSCs tumors (Fig. 3A-3C ). Similar results were seen in ZR-75-30 but not in MDA-MB-231 cell line (Figs. 2D,  3D) . Again, compared with ZR-75-30 tumor cells, cells within the MCF7 tumor were more potentially promoted by hADSCs in the aspects of angiogenesis and proliferation. These data indicated that hADSCs contribute to the angiogenesis and proliferation of MCF7 and ZR-75-30 tumor cells.
hADSCs Increase the CXCL1 and CXCL8 Concentration in Tumor Microenvironment
To identify the angiogenic cytokines production of different tumor tissues, cytokines contents in tumor tissue lysis (15 days) were determined by human angiogenesis array and human cytokine array. The data indicated that compared with MCF7 injected alone, the co-injected group has a higher CXCL1, CXCL8, and GM-CSF expression, while CXCL4 were downregulated. Among those cytokines, the change in CXCL1 and CXCL8 expression were the most obvious (Fig. 4A, 4B ). This result was further confirmed by ELISA to detect the CXCL1/8 concentration on 9, 12, and 15 days after injection Two shRNAs for CXCL1 were selected. MCF7, hADSC, MCF7 1 hADSC, MCF7-sh1 1 hADSC, MCF7-sh2 1 hADSC, MCF7 1 hADSC-sh1, and MCF7 1 hADSC-sh2 were cultured in vitro for 48 hours. CXCL1 levels in the medium were determined by ELISA. Lower: Two shRNAs for CXCL8 were selected. MCF7, hADSC, MCF7 1 hADSC, MCF7-sh1 1 hADSC, MCF7-sh2 1 hADSC, MCF7 1 hADSC-sh1, and MCF7 1 hADSC-sh2 were cultured in vitro for 48 hours. CXCL8 levels in the medium were determined by ELISA. Data are shown as means 6 SEM. Statistical significance was assessed by unpaired, two-tailed Student's t test (**, p < .01; *, p < .05). Abbreviation: hADSC, human adipose-derived mesenchymal stem cell.
Wang, Liu, Jiang et al. 2065 www.StemCells.com V C AlphaMed Press 2017 (Fig. 4C) . These results indicate that CXCL1/8 may account for the higher vascularity in co-injected group. We undertook to determine the source of the CXCL1/ 8 produced in co-injected group. We stably reduced the expression of CXCL1 in MCF7 cells by about 80% using short hairpin RNA (Supporting Information Fig. S4 ). However, subsequent coculture of these MCF7 cells with hADSCs continued to allow accumulation of CXCL1 in the culture supernatants. This suggested that hADSCs may be the source of CXCL1. Indeed, inhibition of CXCL1 expression in hADSCs using the same shRNA resulted in more than 85% reduction in CXCL1 protein levels in the cocultures, further indicating that the hADSCs were the major source of the CXCL1 (Fig. 4E) . Similar, we found CXCL8 was also mainly derived from hADSCs (Fig.  4E) .
Compared with ZR-75-30 tumors, CXCL1/8 concentration in ZR-75-30 1 hADSCs tumors only had a small but statistically significant increase (Fig. 4D) . We speculated that unlike MCF7 tumor cells, hADSCs and ZR-75-30 tumor cells spontaneously expressed CXCL1/8 (Supporting Information Fig. S5 ).
Thus, ZR-75-30 tumor cells may compensate for the function of hADSCs by secreting CXCL1/8, which may be a reasonable explanation for the fact that hADSCs display greater promotion effects on MCF7 cells than that on ZR-75-30 cells. Similar to ZR-75-30 cells, MDA-MB-231 cells also expressed CXCL1/ 8 spontaneously; however, the CXCL1/8 concentration did not increase in MDA-MB-231 1 hADSCs tumors (Supporting Information Fig. S5 ). The interaction between hADSCs and BCCs may be complicated; however, our results indicated that the CXCL1/8 concentration in hADSCs 1 BCCs tumors may be a critical factor to explain the different effects hADSCs showed on BCCs. We chose to focus further analysis on the MCF7 tumor model, because it displayed much greater increase in hADSCs-induced angiogenesis and proliferation.
CXCL1 and CXCL8 do not Modify In Vitro Proliferation of MCF7 Cells
Previous study demonstrated that CXCL1 and CXCL8 were upregulated in breast cancer [26] . To determine whether CXCL1 and CXCL8 were responsible for the higher vascularity, Figure 5 . CXCL1 and CXCL8 do not modify in vitro proliferation of MCF7 cells directly. (A): Matrigel plug assay was conducted with recombinant CXCL1/8. BALB/c nude mice (6 weeks of age) were given subcutaneous injections of 500 ml of matrigel containing vehicle, CXCL1 or CXCL8, or CXCL1 and CXCL8 at 500 ng/ml, respectively. Seven days later, the plug was fixed and stained for CD31 and it was statistically significant between each groups (p < .05). (B): The proliferation rate of MCF7 cells was determined with a Cell Counting Kit-8 at 0, 24, 48, and 72 hours by treatment with vehicle, CXCL1 or CXCL8, or CXCL1 and CXCL8 at 10 ng/ml or 100 ng/ml. (C): The CXCR1 and CXCR2 on the MCF7 cells were analyzed by flow cytometry. Scale bar 5 50 lm. Data are shown as means 6 SEM. Statistical significance was assessed by unpaired, two-tailed Student's t test. (**, p < .01; *, p < .05, ns, no significance).
we conducted matrigel plug assay with recombinant CXCL1/8. The data indicated that CXCL1 or CXCL8 alone could promote angiogenesis, and combined use CXCL1 and CXCL8 promoted angiogenesis to an even greater extent (Fig. 5A) . To determine whether CXCL1 and CXCL8 promote the growth of MCF7 cells by acting on tumor cells directly, we performed cell viability assay with a cell counting kit-8 assay. The data indicated that CXCL1 or CXCL8 alone, or combined use CXCL1 and CXCL8 could not facilitate the proliferation of MCF7 cells (Fig. 5B) . Next, we detected the CXCR1 and CXCR2, receptors of CXCL1 and CXCL8, in MCF7 cells. We observed that CXCR1 and CXCR2 expression were extremely low in MCF7 cells (Fig. 5C ). These results indicated that CXCL1 and CXCL8 could not promote the proliferation of MCF7 cells directly, which may be attributed to the lack of relevant receptors in MCF7 cells.
hADSCs-Derived CXCL1 and CXCL8 Increase Migration and Tube Formation of HUVECs
To confirm our in vivo findings that hADSCs promote angiogenesis, we examined the effect of hADSCs-derived CXCL1/8 on endothelial cell migration and capillary tube formation. We observed a significantly enhancement of migration and tube formation ability in HUVECs incubated with coculture CM compared with HUVECs incubated with MCF7 CM alone (Fig. 6A-6C ). Neutralizing antibodies against either CXCL1 or CXCL8 interfered with the migration and capillary tube formation of HUVECs, and combined use of the two antibodies consolidated this process slightly. Both CXCL1 and CXCL8 bind to CXCR1/2 receptor [27] , inhibition of CXCL1/8-CXCR1/2 signaling with a CXCR1/2-specific antagonist, SCH527123 (10 lM), significantly inhibited migration and capillary tube formation of HUVECs (Fig. 6A-6C ). These results indicated that CXCL1/8 derived from hADSCs can promote HUVECs migration and tube formation directly by signaling via their receptors CXCR1 and CXCR2.
SCH527123 Attenuate Angiogenesis and Tumor Growth in Co-Injected Group
To further understand the role of CXCL1/8 in breast cancer progression, nude mice injected with MCF7 alone or with hADSCs were administrated with SCH527123 (50 mg/kg/day). After 28 days mice were killed, we indicated that SCH527123 can only reduce the tumor growth of co-injected group (Fig.  7A, 7B) , which means hADSCs-derived CXCL1/8 may benefit the growth of breast cancer. To understand the underlying mechanisms, microvessel density was measured by CD31 immunohistochemistry staining and the microvessel density is about two-folds higher in co-injected mice than MCF7 alone. However, after inhibition of CXCL1/8-CXCR1/2 signaling by treated with SCH527123, the microvessel density in co-injected group was significantly decreased. SCH527123 had limited effect on the growth or microvessel density of MCF7 injected mice (Fig. 7C, 7D) . Besides, SCH527123 also decreased the number of Ki-67-positive cells in MCF7 1 hADSCs tumors (Fig. 7C, 7E) . Those results suggested that hADSCs-derived CXCL1/8 can increase the microvessel density in tumor microenvironment and thus promote breast cancer growth.
DISCUSSION
hADSCs are a stem cell population of cells with various potential therapeutic applications. Although current clinical trials have demonstrated a good safety profile of hADSCs [28] , hADSCs can become mobilized from fat tissue, recruited by tumors, and promote cancer progression [27] . Additional, higher number of hADSCs could be inoculated close to the cancer bed through transplantation of autologous fat for reconstructive purposes. Thus, transference of adipose tissue or hADSCs to the potential tumor beds may result in unpredictable risks. The results of this study demonstrated that CXCL1/8 derived from hADSCs could promote the angiogenesis of breast tumors xenografts, and further resulted in proliferation of the tumor cells.
Pathways that involved in ADSCs promoting breast cancer progression were quite different. For instance, ADSCs can induce epithelial-mesenchymal transition in the cancer cells in a PDGF-D paracrine fashion [29] . In addition, HGF/c-Metmediated crosstalk between ADSCs and BCCs controls tumor self-renewal potential [16] . Obesity was identified as a negative prognostic factor in cancer [30] , obesity status of the donors also influences the properties of hADSCs. Under the influence of obesity-derived factors, hADSCs may possess properties that different from hADSCs isolated from a thin individual in their secretory profile, angiogenic potential, and invasive capacity [22, 31] . It is worth noting that ADSCs isolated from obese women enhances proliferation and metastasis of estrogen receptor positive breast cancers, indicating that ADSCs may be a significant factor in obesity-associated breast cancer development [21] . In this study, we isolated hADSCs from the abdominal subcutaneous adipose tissue of obese subjects (BMI > 30), our results indicated that, after coinjection with hADSCs, compared with ZR-75-30 and MDA-MB-231 tumor cells, MCF7 tumor cells were more potentially Further studies need to be conducted to investigate whether hADSCs isolated from a thin individual also have similar effects.
We detected the different cytokines in MCF7 and MCF7 1 hADSCs tumors using cytokine array at early stage. CXCL1/8 was much higher in MCF7 1 hADSCs tumors as long as 15 days after injection. MCF7 cells do not secrete CXCL1/8, while CXCL1/8 secretion levels in all the three ADSCs from different person were extremely high. Hence, we speculated that hADSCs were the major source of CXCL1/8. Using lentivirus-expressing shRNA, we verified CXCL1/8 in MCF7 1 hADSCs tumors were mainly derived from hADSCs. Interestingly, unlike MCF7 tumor cells, ZR-75-30 tumor cells spontaneously expressed CXCL1/8. Besides, the CXCL1/8 concentration was increased moderately in ZR-75-30 1 hADSCs tumors. In this study, hADSCs displayed greater promotion effects on MCF7 tumor angiogenesis than that on ZR-75-30 tumor in vivo. A reasonable explanation was that, ZR-75-30 tumor cells may partially compensate for the function of hADSCs by secreting CXCL1/8.
With respect to the ERa-cell line MDA-MB-231, we found that hADSCs did not enhance cancer cell growth. This observation was consistent with previous findings that mesenchymal stem cells did not alter MDA-MB-231 tumor growth kinetics [24, 25] . Our results indicated that the ERa-cell line MDA-MB-231, a highly aggressive BCC line, is more cell autonomous than MCF7 cells, which requires estrogen tablets or co-injection with fibroblasts to effectively form xenografts [32] . Similar to ZR-75-30 cells, MDA-MB-231 also expressed CXCL1/8 spontaneously, interestingly, the concentration of CXCL1/8 did not increase in MDA-MB-231 1 hADSCs tumors. Altogether, we speculated that the CXCL1/8 concentration in BCCs 1 hADSCs tumor may be a key point to understand the different effects hADSCs showed on BCCs. Higher increase in CXCL1/8 in BCCs 1 hADSCs tumor may result in higher angiogenesis and tumor growth. CXCL1/8 may display growth-promoting effects in breast cancer and other cancers by acting on tumor cells directly [33] . They also could promote angiogenesis through both autocrine and paracrine signaling in gastric and prostate cancers [34, 35] . Consistent with previous study, we found that recombinant CXCL1/8 protein did not modify in vitro proliferation of MCF7 BCCs, which may because of the lack of CXCR1/ 2 receptor in MCF7 cancer cells [36] . We speculated that CXCL1/8 derived from hADSCs could benefit tumor growth by increasing tumor microvessel density, but not by acting on tumor cells directly.
Angiogenesis is of critical significance for tumor development and the blood vessel in the tumor environment could provide sufficient nutrients and oxygen to the tumor cells [37] . Several anti-angiogenic drugs have been developed to block tumor angiogenesis [38, 39] , however, these drugs have not satisfied expected demand in clinical trials [40] . To confirm our hypothesis that hADSCs promote breast tumor growth by facilitating angiogenesis, we examined the effect of hADSCs-derived CXCL1/8 on endothelial cell migration and capillary tube formation. We observed a significantly enhancement of migration and tube formation ability in HUVECs incubated with coculture CM compared with HUVECs incubated with MCF7 CM alone. Inhibitory antibodies against either CXCL1 or CXCL8 inhibited the effect of coculture CM, and combined use of the two antibodies consolidated this process slightly.
SCH527123 is a potent antagonist of both CXCR1 and CXCR2 and has shown antitumor activity in preclinical colon cancer models [41] . In our study, SCH527123 (10 lM) also significantly inhibited migration and tube formation ability in HUVECs incubated with coculture CM. Besides, SCH527123 (50 mg/kg/day) attenuated the angiogenesis and tumor growth significantly in co-injected group in vivo. Thus, we demonstrated hADSCs-derived CXCL1/8 could promote the angiogenesis both in vitro and in vivo and therefore serve as a potential novel therapeutic target. However, inhibition of CXCL1/8-CXCR1/2 axis cannot reverse the promotion effect in co-injected group totally, which means there are still other mechanisms which remains to be explored.
CONCLUSION
In conclusion, our results demonstrated that hADSCs play a procarcinogenic role in the progression of BCCs through secrete proangiogenic cytokines CXCL1 and CXCL8. Two particular clinical aspects should be addressed. (a) hADSCs can potentially lead to cancer recurrence by activating residual BCCs persisting in tumor bed after mastectomy through promoting angiogenesis. (b) Particularly, applying hADSCs for regenerative approaches such as plastic, cartilage repair, and cardiac surgery should be seriously considered if the patient is coincidentally diagnosed with breast cancer or other cancer types. Although much work remains to be done to fully understand the accurate mechanisms of ADSCs facilitating tumor progression, our results may provide better understanding of safety concerns regarding the clinical application of hADSCs and new insights into tumor biology.
